Sean Maduck, the president of Corcept Therapeutics, has executed a sale of company stock valued at $1.76 million. This transaction is part of his financial management strategy and reflects his holdings in the company. The sale was disclosed in a regulatory filing, which is standard practice for corporate executives. Corcept Therapeutics is known for its focus on developing treatments for cancer and other serious disorders.
Related Articles
Don't miss out on breaking stories and in-depth articles.